CBD reduced brain inflammation and improved memory in diabetic rats with impaired brain blood flow

CBD treatment improved memory and reduced brain inflammation markers in middle-aged diabetic rats subjected to chronic cerebral hypoperfusion, though it did not affect neuroplasticity markers.

Santiago, Amanda Nunes et al.·Neurotoxicity research·2019·Preliminary EvidenceAnimal StudyAnimal Study
RTHC-02276Animal StudyPreliminary Evidence2019RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

Diabetes worsened cognitive deficits from chronic cerebral hypoperfusion in middle-aged rats. CBD (10 mg/kg daily for 30 days) improved memory performance and reduced hippocampal levels of multiple inflammation markers (iNOS, Iba1, GFAP, arginase 1). CBD also attenuated the BDNF decrease caused by hypoperfusion. CBD did not affect neuroplasticity markers (GAP-43, synaptophysin) and caused weight loss.

Key Numbers

CBD dose: 10 mg/kg daily for 30 days. Reduced iNOS, Iba1, GFAP, and arginase 1 in hippocampus. Preserved BDNF levels. Did not affect GAP-43 or synaptophysin. Caused weight loss.

How They Did This

Middle-aged rats (14 months) were made diabetic with streptozotocin, subjected to chronic cerebral hypoperfusion surgery, then treated with CBD 10 mg/kg/day for 30 days. Memory, inflammation markers, and neuroplasticity markers were assessed.

Why This Research Matters

Diabetes and aging together dramatically increase the risk of cognitive decline from reduced brain blood flow. Finding that CBD can protect against this combined insult suggests it targets the inflammatory pathway that worsens the damage.

The Bigger Picture

With diabetes and vascular disease both increasing globally, the intersection of these conditions with cognitive decline is a growing public health concern. CBD's anti-inflammatory properties may address a key mechanism in this process.

What This Study Doesn't Tell Us

Animal study using a pharmacological diabetes model. Only one CBD dose tested. The weight loss effect of CBD needs further investigation. Results may not translate directly to humans.

Questions This Raises

  • ?Would CBD be effective in human patients with diabetes and cerebrovascular disease?
  • ?Is the memory improvement driven entirely by inflammation reduction?
  • ?Could combining CBD with standard diabetes treatment provide synergistic protection?

Trust & Context

Key Stat:
CBD reduced four inflammation markers in the hippocampus
Evidence Grade:
Preliminary: single animal study with one dose in a specific disease model.
Study Age:
Published in 2019.
Original Title:
Effects of Cannabidiol on Diabetes Outcomes and Chronic Cerebral Hypoperfusion Comorbidities in Middle-Aged Rats.
Published In:
Neurotoxicity research, 35(2), 463-474 (2019)
Database ID:
RTHC-02276

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

What is chronic cerebral hypoperfusion?

It refers to chronically reduced blood flow to the brain, which can occur with aging, diabetes, and cardiovascular disease. Over time, it leads to cognitive decline and increases dementia risk.

Why did CBD cause weight loss?

CBD-induced weight loss has been observed in other studies and may relate to its effects on appetite regulation, fat metabolism, or energy expenditure. This effect was seen in both sham and hypoperfusion groups.

Read More on RethinkTHC

Cite This Study

RTHC-02276·https://rethinkthc.com/research/RTHC-02276

APA

Santiago, Amanda Nunes; Mori, Marco Aurélio; Guimarães, Francisco Silveira; Milani, Humberto; Weffort de Oliveira, Rúbia Maria. (2019). Effects of Cannabidiol on Diabetes Outcomes and Chronic Cerebral Hypoperfusion Comorbidities in Middle-Aged Rats.. Neurotoxicity research, 35(2), 463-474. https://doi.org/10.1007/s12640-018-9972-5

MLA

Santiago, Amanda Nunes, et al. "Effects of Cannabidiol on Diabetes Outcomes and Chronic Cerebral Hypoperfusion Comorbidities in Middle-Aged Rats.." Neurotoxicity research, 2019. https://doi.org/10.1007/s12640-018-9972-5

RethinkTHC

RethinkTHC Research Database. "Effects of Cannabidiol on Diabetes Outcomes and Chronic Cere..." RTHC-02276. Retrieved from https://rethinkthc.com/research/santiago-2019-effects-of-cannabidiol-on

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.